20 Future Welsh HealthTech and MedTech Leaders

Nelson Advisors
Apr 29
18 min read

The Vanguard of Welsh HealthTech and MedTech: Strategic Analysis of Emerging Leadership and Innovation Clusters

The landscape of life sciences in Wales has undergone a fundamental transformation, transitioning from a collection of isolated research successes into a cohesive, globally competitive ecosystem that has reached a critical inflection point in 2026.

This sector, now generating an annual turnover of approximately £3.59 billion and employing over 13,000 highly skilled professionals across 287 companies, has become a cornerstone of the Welsh economy and a vital component of the United Kingdom’s broader industrial strategy.

The year 2026 is widely regarded by industry analysts as a "breakthrough year," characterised by a maturation of financing conditions, a resurgence in strategic M&A activity and a rapid acceleration in the adoption of artificial intelligence and digital diagnostics within the National Health Service (NHS) Wales.

This report provides an analysis of 20 future leaders who are orchestrating this evolution, contextualising their contributions within the scientific, economic and clinical frameworks of the mid-2020s.

The Economic and Strategic Framework of the 2026 Breakthrough

To understand the rise of new leadership in Welsh HealthTech, it is necessary to examine the structural shifts that occurred between 2024 and 2026. After a period of tentative recovery following the global economic volatility of 2024, the Welsh life sciences sector entered 2026 with a newfound confidence.

This shift was driven by the intersection of pharmaceutical "patent cliffs", where major products lost exclusivity, forcing large companies to replenish their pipelines through the acquisition of smaller innovators and the increasing availability of targeted capital from sources such as the Development Bank of Wales and the Horizon Europe scheme.

Wales has positioned itself as an ideal location for scaling HealthTech businesses due to its "One Wales" model, which facilitates streamlined access to clinical trials, a comprehensive genetic and health databank (SAIL) and a connected support system involving eight world-class universities.

The infrastructure is anchored by specialised clusters such as the South Wales semiconductor network, which integrates research and development (R&D) with high-value manufacturing, and North Wales’ M-SParc, which fosters collaboration between academia and startups.

Table 1: Economic Indicators and Sectoral Strengths (2025-2026)

Indicator	Value/Metric	Strategic Significance
Annual Sector Turnover	£3.59 Billion	Foundation for national economic resilience.
Export Value	£1.24 Billion	Demonstrates global competitiveness of Welsh MedTech.
Total Employment	13,000+	High-density cluster of PhD-level and technical roles.
Inward Investment	£23 Million (Norgine)	Capacity expansion in essential medicine production.
Key Growth Areas	AI Diagnostics, Genomics	Aligned with the NHS 10-Year Plan and value-based care.
Venture Capital	$140 Million (Series A)	Record-breaking investment in neuropsychiatry.

Profiles in Leadership: The Architects of the Future

The following 20 leaders have been identified based on their clinical impact, scientific novelty, commercial success and strategic influence on the Welsh and global HealthTech landscape.

1. Dr. Sabih Chaudhry: CEO and Founder, Afon Technology

Dr. Sabih Chaudhry stands as a preeminent figure in the world of metabolic health, leading Afon Technology in the pursuit of the "holy grail" of diabetes care: a non-invasive continuous glucose monitor. Based in Monmouthshire, Chaudhry has steered the development of Glucowear, a wearable device that utilises ultra-low power microwave technology to provide real-time glucose readings without the need for skin penetration.

The innovation addresses a global market of millions who currently rely on painful finger-pricks or invasive sensors. Under Chaudhry’s leadership, the company successfully lobbied for continued involvement in the Horizon Europe scheme post-Brexit, securing essential funding that has enabled the scaling of its specialist team.

By late 2025, Chaudhry represented Welsh innovation at the Wales Investment Summit, positioning Glucowear for a comprehensive worldwide launch in 2026. His leadership is defined by a commitment to clinical rigor, having moved through extensive trials with NHS partners to ensure that Welsh-engineered solutions have a global clinical impact.

2. Dr. Ivana Magovčević-Liebisch: President and CEO, Draig Therapeutics

The appointment of Dr. Ivana Magovčević-Liebisch as CEO of Draig Therapeutics signaled a new era for Welsh biotechnology, specifically in the field of neuropsychiatry. Draig Therapeutics, a Cardiff University spin-out, emerged from stealth in mid-2025 with a $140 million (£107 million) Series A investment—the largest in the history of the Welsh life sciences sector. Magovčević-Liebisch leads a clinical-stage company targeting the brain’s glutamate and GABA systems, which are fundamental to mood, emotion, and cognition.

Her leadership is critical as Draig advances its lead candidate, DT-101, into Phase 2 clinical trials for Major Depressive Disorder (MDD). Magovčević-Liebisch’s strategic vision involves leveraging the company’s deep scientific roots in Wales to develop treatments that provide faster and more sustainable relief than traditional antidepressants, effectively addressing a massive unmet global clinical need.

3. Professor Simon Ward: Chief Scientific Officer and Co-founder, Draig Therapeutics

Professor Simon Ward is the scientific vanguard of the Cardiff-based neuropsychiatry cluster. As the Director of the Medicines Discovery Institute (MDI) at Cardiff University, Ward’s career has been dedicated to bridging the gap between fundamental neuroscience and commercial drug development.

His expertise in modulating core glutamate and GABA pathways provided the intellectual foundation for Draig Therapeutics. Ward’s leadership style is defined by "translational excellence," a methodology that integrates academic research with industrial-scale drug discovery processes. Under his guidance, the MDI was launched with support from the Welsh Government’s Sêr Cymru scheme, eventually leading to the creation of Draig and the subsequent record-breaking investment that has validated the Welsh research ecosystem on a global scale.

4. Professor John Atack: Head of Biology and Co-founder, Draig Therapeutics

Working alongside Professor Ward, Professor John Atack brings decades of experience from the National Institutes of Health (NIH) and major pharmaceutical companies like Johnson & Johnson’s Janssen Pharmaceuticals. Atack’s role as Co-founder and Head of Biology at Draig is focused on the rebalancing of chemical neurotransmitters in the brain to treat complex psychiatric conditions.

His leadership has been instrumental in the rapid progression of the Draig pipeline, which aims to advance multiple drug candidates toward clinical development by 2026. Atack’s presence in the Welsh ecosystem exemplifies the "reverse brain drain" effect, where seasoned industry veterans return to academia to launch high-growth startups, thereby mentoring the next generation of Welsh pharmacologists and biologists.

5. Iestyn Foster: CEO and Co-founder, Amotio

Iestyn Foster has emerged as a central leader in the MedTech sector through his work at Amotio, a company redefining orthopaedic revision surgery. With over 35 years of experience in clinical orthopaedics and commercialisation, Foster leads the development of patient-specific technology for the safe removal of bone cement during joint replacement surgery.

This is a critical challenge, as by 2030, the global population aged 60 and older is projected to reach 1.4 billion, driving a massive increase in joint revision procedures. Under Foster’s leadership, Amotio secured an £810,000 pre-seed round, led by the Development Bank of Wales, which has allowed the company to move its prototype technology toward preclinical testing and regulatory approval.

Foster’s strategic approach emphasises "value-based care," focusing on reducing surgical operative time and improving recovery outcomes, thereby easing the burden on healthcare systems worldwide.

Table 2: Major Investment Rounds and Financial Milestones (2024-2026)

Company	Leader	Round Amount	Funding Source	Key Focus Area
Draig Therapeutics	I. Magovčević-Liebisch	$140 Million	Access Biotech, SV Health	Neuropsychiatry.
Amotio	Iestyn Foster	£810,000	Dev. Bank of Wales, NLC	Orthopaedic Revision.
Awen Oncology	Ramsey McFarlane	7-Figure (Multi)	Dr. Urs Spitz, Start Codon	Rare Bone Cancers.
Norgine	Janneke van der Kamp	£23 Million	LSIMF (UK Gov)	Pharma Manufacturing.
SAIL Databank	University Team	£4.55 Million	Health & Care Research Wales	Population Data Science.
HTSG	Samit Biswas	£500,000 (Rev)	Bootstrapped/Commercial	Remote Patient Monitoring.

6. Dr. Ramsey McFarlane: CEO and Co-founder, Awen Oncology

Dr. Ramsey McFarlane is a pivotal figure in the North Wales biotechnology scene, leading Awen Oncology from its headquarters at M-SParc on Anglesey. Awen Oncology, a spin-out from Bangor and Cardiff Universities, focuses on the discovery of innovative cancer therapeutics that target specific biological mechanisms dormant in healthy tissue but active in tumours.

McFarlane’s leadership has been characterized by a successful multi-stage funding strategy, securing a six-figure equity investment from the Development Bank of Wales and the Start Codon accelerator, followed by a seven-figure round led by biotech investor Dr. Urs Spitz in early 2026. McFarlane’s vision for Awen involves creating high-value PhD-level scientific jobs in North Wales while developing first-in-class therapies for rare bone cancers with significant unmet needs.

7. Dr. Jane Wakeman: CSO and Co-founder, Awen Oncology

Dr. Jane Wakeman provides the scientific leadership that underpins Awen Oncology’s therapeutic pipeline. Her work centers on "oncogenic developmental factors," genes that unexpectedly activate during the onset of cancer. Wakeman’s leadership at Awen has transitioned over 15 years of fundamental academic research, supported by Cancer Research Wales, into a commercial enterprise capable of global impact.

As Chief Scientific Officer, she oversees the integration of computational chemistry and drug discovery expertise to identify new therapeutic candidates. Wakeman’s presence at the forefront of Awen demonstrates the power of long-term academic-charity partnerships in catalysing the Welsh biotech sector.

8. Dr. Martin Scurr: CSO and Founder, ImmunoServ

Dr. Martin Scurr has redefined the landscape of immune monitoring in Wales. As a Research Fellow at Cardiff University and CSO of ImmunoServ, Scurr led the development of specialized T-cell testing kits that measure a person’s long-term protection against infectious diseases like COVID-19 and bird flu. His work earned ImmunoServ the St David Award for Innovation, Science and Technology in 2025, the highest national accolade in Wales.

Scurr’s leadership is notable for its move toward "at-home" diagnostics, allowing individuals to monitor their own T-cell immunity after infection or vaccination. Based at the Cardiff Medicentre, Scurr has successfully fostered collaborations between academia and industry to ensure that immune monitoring becomes a standardized component of global public health surveillance.

9. Ravi Nalliah: CEO and Founder, TrakCel

Ravi Nalliah is the principal orchestrator of the digital supply chain for advanced therapies in Wales. As the CEO of TrakCel, Nalliah leads a company that provides the essential software platform for managing the international supply chain of cell and gene therapies (CGTs). TrakCel’s technology ensures "needle-to-needle" compliance and traceability, which is critical for autologous therapies like CAR-T, where a patient’s own cells are modified and returned.

Nalliah’s background in finance and supply chain management has been vital in positioning TrakCel as a market leader, supporting both clinical trials and commercial deployments globally. His leadership is a testament to the importance of "digital infrastructure" as a primary enabler for the next generation of medicine.

10. Hannah Madan: Co-founder, Prima Mente

Hannah Madan represents the next generation of AI-driven HealthTech leadership. As a Co-founder of Prima Mente, she is spearheading a mission to transform the diagnosis of neurodegenerative diseases such as Alzheimer’s and dementia.Prima Mente’s innovation centers on the use of Pleiades, an epigenetic foundation model that can identify early signs of neurological disease with unprecedented accuracy.

Under Madan’s leadership, the company has partnered with the Aneurin Bevan University Health Board in the UK-wide SANDBOX study, making Wales the first region to open a trial site for this cutting-edge diagnostic tool. Madan’s approach emphasises breaking down neurodegenerative conditions into molecular signatures, much like modern oncology, to enable personalised and early intervention.

11. Samit Biswas: CEO and Founder, Health Tech Services Group (HTSG)

Samit Biswas is a veteran leader who has successfully bridged the gap between healthcare logistics and remote patient monitoring. Founded in India and expanded to the UK, HTSG has established a significant presence in Wales, operating from the Bay Technology Centre in Port Talbot. Biswas has pioneered the "Clinic At Home" and "Care Safe Mobility" models, which leverage technology to provide high-quality care to elderly and vulnerable populations outside of traditional hospital settings.

His leadership was recognized by his election as a Senior Associate of the Royal Society of Medicine in 2024. Biswas’s vision is centred on revolutionising home-based healthcare, ensuring that digital tools like the WatchRx remote monitoring system are seamlessly integrated into the daily lives of patients.

12. Samantha Horwill: Managing Director and Co-founder, Yma

Samantha Horwill is a leading voice in the redesign of community-led healthcare models in Wales. As the Co-founder of Yma, Horwill has spent over 20 years developing and delivering service models that prioritize collaboration over organizational silos. Her role in reviewing Technology Enabled Care (TEC) for the Mid Wales Healthcare Collaborative informed Yma’s mission to enable "exceptional care" through national "Once for Wales" implementations.

Horwill’s leadership is particularly relevant in the context of the NHS Wales Performance Framework, which emphasizes shifting resources to the community and reducing unwarranted variations in care. Under her guidance, Yma has become a key partner for health boards seeking to implement sustainable, citizen-centered service changes.

13. Professor Peter Bannister: Board Member, Life Sciences Hub Wales

Professor Peter Bannister is a strategic leader who integrates deep academic expertise with industrial commercialization. As a Board Member of Life Sciences Hub Wales and Managing Director of Romilly Life Sciences, Bannister advises on evidence-led digital product strategies for businesses specialising in diagnostics and digital treatment pathways.

With a doctorate in medical imaging and experience partnering with global firms like Rolls Royce, Bannister provides the high-level governance required to turn Welsh innovations into scalable global businesses. His leadership is focused on shifting healthcare from reactive to preventative models, utilizing AI and data science to improve patient outcomes while reducing system-wide costs.

14. Cari-Anne Quinn: CEO, Life Sciences Hub Wales (LSHW)

Cari-Anne Quinn serves as the national "connector" for the Welsh life sciences ecosystem. As CEO of LSHW, she leads the organisation’s mission to accelerate the adoption of innovative solutions into the front-line health and social care sectors.

Quinn’s leadership has been instrumental in brokering collaborations between industry, academia, and the NHS, particularly in priority areas such as digital health and precision diagnostics. Under her current strategy, LSHW has supported tens of thousands of patients through the adoption of new technologies and created a robust pipeline of commercial opportunities that generate economic value for Wales. Quinn is widely regarded as a central figure in making Wales a "compact, collaboration-ready" ecosystem for international investors.

15. Jacqueline Totterdell: Chief Executive, NHS Wales

Jacqueline Totterdell holds the most significant clinical leadership role in the nation, serving as the Chief Executive for NHS Wales and Director General for Health, Social Care and Early Years. Her leadership is focused on the delivery of "A Healthier Wales," a strategic plan that emphasises value-based healthcare and the integration of digital tools to improve physical and mental well-being.

Totterdell is responsible for aligning the diverse health boards of Wales behind a single performance framework that prioritises population health and timely access to care. Her commitment to innovation is evidenced by her role as a keynote speaker at major collaborative conferences like MediWales Connects, where she advocates for the scaling of change and the adoption of new clinical processes across the whole system.

16. Professor Isabel Oliver: Chief Medical Officer for Wales

Professor Isabel Oliver is a critical architect of the clinical priorities that drive MedTech innovation in Wales. As the Chief Medical Officer, she focuses on harnessing the "genomics revolution" and digital transformation to deliver more precise, personalised healthcare. Oliver’s leadership is central to the integration of genomics into cancer diagnosis and treatment, as well as its application in rare diseases and population health.

Her presence as a keynote speaker at the M-SParc Innovation Conference in 2025 highlighted the importance of North Wales as a growing influence in the national healthcare landscape. Oliver provides the clinical "north star" for innovators, ensuring that new technologies are developed in response to the most pressing health needs of the Welsh population.

17. Monica Martins: Clinical Team Lead, Swansea Bay University Health Board

Monica Martins represents the vanguard of professional workforce innovation within the NHS. As the Clinical Team Lead in Nuclear Medicine, Martins was named the Overall Winner of the Advancing Healthcare Awards Cymru 2025. Her leadership in developing a "Non-Medical Bone Densitometry (DXA) Reporting Workforce" has been hailed as a breakthrough in addressing diagnostic backlogs.

By creating a sustainable, non-medical reporting framework, Martins has effectively expanded the capacity of the NHS to diagnose osteoporosis and other bone-related conditions, providing a blueprint for how HealthTech adoption must be accompanied by workforce evolution.

18. Dean Fyfield: Clinical Computing Technologist, Swansea Bay University Health Board

Dean Fyfield is a prominent "Rising Star" in the technical leadership of modern medicine. As a Clinical Computing Technologist, Fyfield became the first professional in his field to be registered with the Register for Clinical Technologists, specialising in the management of software medical devices and radiotherapy hardware. His role is crucial in the 2026 landscape, where the boundary between medical equipment and software is increasingly blurred.

Fyfield’s leadership in ensuring the safety and efficacy of digital radiotherapy tools represents the highly specialized technical talent that is essential for the future of digital oncology in Wales.

19. Professor Keith Lloyd: Chair, Health Technology Wales (HTW) Appraisal Panel

Professor Keith Lloyd is a cornerstone of the evaluative leadership that determines which technologies reach the Welsh patient. As a Professor of Psychiatry at Swansea University and Director of the Institute of Life Science, Lloyd chairs the HTW Appraisal Panel, which issues authoritative guidance on non-medicine health and social care technologies.

His leadership ensures that innovation in Wales is evidence-based and cost-effective. Lloyd has a long-standing interest in MedTech and "SportsTech" innovation, and his work at the Institute of Life Science has been vital in creating the emerging clusters that now define the Swansea Bay area.

20. Pryderi ap Rhisiart: Managing Director, M-SParc

Pryderi ap Rhisiart is the primary enabler of HealthTech innovation in North Wales. As the Managing Director of M-SParc, Wales’ first dedicated science park, he has built a hub for collaboration between entrepreneurs, researchers, and the NHS. Under his leadership, M-SParc has become home to breakthrough companies like Awen Oncology and hosted major national innovation conferences.

Ap Rhisiart’s vision is centered on ensuring that North Wales leads the way in transforming health and care through remote diagnostics and digital tools, leveraging the region’s connection to Bangor University to create a forward-looking business community.

Technological and Clinical Deep Dives: The Innovation Mechanisms

The leadership described above is underpinned by specific scientific and technological paradigms that have matured by 2026. These innovations are being developed within a "One Wales" framework that prioritises rapid clinical evaluation and adoption.

Neuropsychiatry: The Glutamate and GABA Paradigm

The work of Professors Ward and Atack at Draig Therapeutics represents a major shift in neuropsychiatric drug discovery. Traditional treatments for depression and anxiety have largely focused on the monoamine system (serotonin and norepinephrine). However, Draig’s research targets the glutamate and GABA systems, the brain’s primary excitatory and inhibitory neurotransmitters.

By rebalancing these networks, Draig’s lead candidate DT-101 aims to provide symptom relief in a fraction of the time required by standard SSRIs, potentially reducing the high rates of relapse and inadequate relief seen in the current standard of care. This focus has attracted global venture capital because it targets the fundamental biological drivers of neuropsychiatric disease rather than just the symptoms.

Digital Oncology: Automated Radiotherapy Planning

At Velindre University NHS Trust, leadership in radiotherapy has moved toward full automation. Working with Cardiff University, the team developed EdgeVcc, an automated treatment planning solution. Radiotherapy planning has traditionally been a time-consuming, manual process performed by healthcare scientists.

EdgeVcc uses advanced algorithms to design precise, personalised cancer treatment plans in a fraction of the usual time. This innovation has immediate clinical implications: it reduces the risk of treatment delays, ensures consistency in plan quality regardless of geography, and allows scientists to focus on the most complex clinical cases.

Metabolic Monitoring: Microwave-Based Glucose Sensing

Afon Technology’s Glucowear represents a significant departure from electrochemical glucose sensing. While traditional CGMs use enzyme-coated filaments inserted under the skin, Glucowear uses ultra-low power microwave signals to detect changes in blood glucose levels through the skin. The technical challenge, successfully navigated by Dr. Sabih Chaudhry’s team, was isolating the glucose signal from other biological variables.

The successful resolution of this problem by 2026 has made Wales a global leader in "wearable metabolic health," attracting manufacturing partnerships that will see the device distributed worldwide.

Table 3: Regional Innovation Clusters and Infrastructure Assets (2026)

Cluster / Asset	Location	Key Leaders	Specialization
M-SParc	Anglesey	Pryderi ap Rhisiart	Low carbon, Digital Health, Biotech.
Cardiff Medicentre	Cardiff	Rhys Pearce-Palmer	Biotech and MedTech incubation.
CISM	Swansea	Swansea Univ. Team	Semiconductor research for MedTech.
Llanfrechfa Medi-Park	Gwent	ABUHB / Industry	Innovation adjacent to Grange Hospital.
SAIL Databank	Swansea	Population Science	Secure health and genetic data access.
Cardiff Health Partners	Cardiff	Strategic Alliance	Translational research and cancer medicine.

Institutional Enablers and Funding Frameworks

The success of these future leaders is inextricably linked to the unique funding and support environment in Wales. The ecosystem has moved toward "patient capital" and collaborative research grants that support the long-term journey from laboratory to market.

The Development Bank of Wales (DBW)

The DBW has become the most active early-stage investor in the Welsh MedTech sector. By 2026, it has successfully pioneered co-investment models where public funds act as a catalyst for private venture capital. For example, the £500,000 equity investment in Amotio enabled the company to attract specialist funding from NLC Health Ventures and Orthopaedic Research UK.

Similarly, the DBW’s investment in Awen Oncology alongside Start Codon provided the stability required for the company to eventually secure a seven-figure round from international investors.

Commercial Research Delivery Wales

This organisation offers a "One Wales" model for clinical trials, providing one contract, one price, and a rapid setup process across all health boards. This streamlined access is a major selling point for leaders like Hannah Madan (Prima Mente) and the Draig Therapeutics team, as it allows them to move their candidates through clinical evaluation faster than in more fragmented healthcare systems.

Table 4: Key Stakeholders and Their Role in the Leadership Pipeline

Stakeholder	Primary Function	Impact on Leadership Development
Life Sciences Hub Wales	Connector / Accelerator	Moves proven ideas into clinical practice faster.
MediWales	Industry Membership	Provides networking, award recognition, and advocacy.
Health & Care Research Wales	Funding / Support	Supports clinical trials and researcher fellowships.
Welsh Government	Policy / Grant Support	SMART capital and international trade programmes.
Cardiff Innovations	Hub / Workspace	Physical home for spin-outs like Draig Therapeutics.
ABHI	Industry Body	Strategic insight through leaders like Neil Mesher.

The "Once for Wales" Implementation Strategy

A recurring theme among the leaders profiled, particularly those within the NHS and community care sector is the "Once for Wales" approach. This strategy aims to eliminate the regional variation in healthcare delivery by adopting single, evidence-based models of care across all seven health boards.

Workforce Evolution: The Advanced Practitioner Model

The leadership of Monica Martins and the highly commended projects from the Advancing Healthcare Awards highlight a major shift toward "Advanced Practitioners". This involves training non-medical staff (such as therapists, nurses, and podiatrists) to take on roles traditionally held by doctors, such as reporting on diagnostic scans or managing complex chronic pathways.

By 2026, this has become a standard method for integrating new HealthTech into the workforce, ensuring that the technology is supported by people with the specific skills needed to interpret and act on its data.

Value-Based Healthcare (VBHC)

Under the leadership of Jacqueline Totterdell and Isabel Oliver, NHS Wales has become a global exemplar of VBHC.This approach focuses on outcomes that matter to patients relative to the cost of care. Leaders in the sector are now required to demonstrate not just that their technology works, but that it delivers measurable improvements in patient quality of life and reduces long-term system demand.

The Spread & Scale Academy, highly commended at the MediWales Innovation Awards, has supported over 1,000 professionals in accelerating innovations that align with this value-based model, reporting over £8.5 million in savings and significant reductions in CO2e emissions.

Strategic Challenges and Future Outlook: The 2027 Horizon

As the Welsh HealthTech sector enters the latter half of the decade, several strategic challenges will define the success of its leaders.

Scaling and Internationalisation

While Wales has demonstrated an exceptional ability to "spin out" companies, the next phase of leadership must focus on "scaling up." Companies like Afon Technology and Draig Therapeutics are now entering the international stage, requiring them to navigate global regulatory environments (such as the FDA in the US) and establish international supply chains.The Welsh Secretary’s 2026 announcement of a new international trade programme is designed to support this expansion, helping Welsh firms capitalise on their domestic success to reach global markets.

Data Governance and AI Scrutiny

With the increasing integration of AI in diagnostics (e.g., Prima Mente and Velindre’s EdgeVcc), leaders must navigate a tightening regulatory landscape. The UK Government’s National Security and Investment Act 2021 has placed greater emphasis on the screening of investments in companies that control large clinical datasets or AI platforms. Leaders will need to prioritise "diligence readiness," ensuring that data governance and IP ownership are impeccable to avoid delays in funding or acquisition.

Table 5: Strategic Growth Sectors in Welsh HealthTech (2026 and Beyond)

Sector	Current Leading Figure	Emerging Innovation	Future Potential
Neuropsychiatry	Ivana Magovčević-Liebisch	Glutamate/GABA Modulation	Global standard for depression care.
Wearables	Dr. Sabih Chaudhry	Microwave Glucose Monitoring	Integration with wider metabolic health apps.
Cell/Gene Therapy	Ravi Nalliah	Supply Chain Orchestration	Enabling commercial-scale advanced therapies.
Digital Oncology	Velindre Trust Leads	Automated AI Planning	Reduced treatment wait times globally.
Home-Based Care	Samit Biswas	Remote Monitoring (WatchRx)	Shift from hospital to community care.
Neuro-Diagnostics	Hannah Madan	Epigenetic AI Models	Early detection of Alzheimer's.

Synthesis and Conclusion

The emergence of these 20 leaders marks the culmination of a decade-long investment in the Welsh life sciences infrastructure. From the semiconductor foundries of Swansea to the biotech laboratories of Anglesey, Wales has created a compact, highly connected ecosystem where innovation is intrinsically linked to clinical need.

The leadership of 2026 is defined by "translational capability", the ability to move seamlessly between the worlds of academic research, clinical practice, and global finance. Whether it is Dr. Sabih Chaudhry’s pursuit of non-invasive monitoring, Dr. Ivana Magovčević-Liebisch’s record-breaking biopharma financing, or Jacqueline Totterdell’s system-wide clinical transformation, the common thread is a commitment to improving patient outcomes through the application of advanced technology.

As Wales looks toward 2027 and beyond, its HealthTech and MedTech leaders are no longer just "rising stars" on a regional stage; they are the architects of a resilient, innovation-led healthcare future that is already delivering measurable benefits to patients both at home and across the world.

The success of the "One Wales" model provides a global blueprint for how small nations can leverage deep scientific expertise and collaborative governance to lead in the most complex and vital industry of the 21st century.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech